Hartmann, Arndt
Schirmacher, Peter
Sterlacci, William
Koch, Winfried
Liesenfeld, David B.
Schif, Birgit
Garbe, Claus
Funding for this research was provided by:
Roche Pharma AG
Article History
Received: 10 May 2018
Revised: 1 October 2018
Accepted: 22 October 2018
First Online: 7 November 2018
Compliance with ethical standards
:
: A Hartmann has received research funding from Sysmex, BioNTech, Nanostring, and Novartis, and has received honoraria from Roche, AstraZeneca, BMS, and MSD, and payment for consultancy or advisory roles from Medoc, Roche, AstraZeneca, BMS, and MSD. P Schirmacher has received research funding from Roche, AstraZeneca, Novartis, Chugai, Thermo Fisher, and Sanofi Aventis, honoraria from Novartis, AstraZeneca, and Roche, and payment for consultancy or advisory roles from Roche, AstraZeneca, Novartis, BMS, MSD, Merck, and Amgen. W Sterlacci has received payment for consultancy or advisory roles from Roche. W Koch is an employee of BDS Koch, which receives payment for statistical services from Roche. B Schif and DB Liesenfeld are employed by Roche. C Garbe has received research funding from BMS, Novartis, and Roche, honoraria from Amgen, BMS, MSD, Novartis, and Roche, travel, accommodation, and other expenses from Amgen, BMS, MSD, Novartis, and Roche, and payment for consultancy or advisory roles from Amgen, BMS, MSD, Novartis, and Roche.
: Ethics approval was obtained at the University of Erlangen-Nürnberg (approval no. 14_13 B dated Feb 19th 2013).
: Informed consent was not required as all data were collected as part of routine testing and were fully anonymized prior to analysis.